Candel Therapeutics, Inc.
Tremor tracks 5 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- CADLCandel Therapeutics, Inc.10Calm
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Running, no new patientsPhase 290 patientsMain results: Dec 31, 2024 - CADLCandel Therapeutics, Inc.10Calm
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Running, no new patientsPhase 3711 patientsMain results: Aug 2024 - CADLCandel Therapeutics, Inc.10Calm
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Running, no new patientsPhase 2187 patientsMain results: Nov 2024 - CADLCandel Therapeutics, Inc.0Calm
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Signing up patientsPhase 245 patientsMain results: Feb 2027 - CADLCandel Therapeutics, Inc.0Calm
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Signing up patientsPhase 3500 patientsMain results: Oct 22, 2031
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
5 sales (0 not pre-planned) · 0 purchases
- Tak Paul PeterChief Executive Officer · Sep 11, 2026Sold 59,379 sharesabout $621 thousand · pre-planned
- Tak Paul PeterChief Executive Officer · Sep 10, 2026Sold 220,866 sharesabout $2.5 million · pre-planned
- Tyagarajan SeshuChief Technology Officer · Aug 17, 2026Sold 7,000 sharesabout $84 thousand · pre-planned
- Barone FrancescaChief Scientific Officer · Jun 29, 2026Sold 23,447 sharesabout $236 thousand · pre-planned
- Tyagarajan SeshuChief Technology Officer · Jun 29, 2026Sold 7,000 sharesabout $70 thousand · pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- An executive or board member joined or left; Shared information with investorsNews report (8-K)Sep 10, 2026
- Shared information with investorsNews report (8-K)Sep 9, 2026
- Quarterly reportQuarterly report (10-Q)Aug 13, 2026
- Shared quarterly resultsNews report (8-K)Aug 13, 2026
- News reportNews report (8-K)Jun 24, 2026